Literature DB >> 25530661

Sample Size Requirements and Study Duration for Testing Main Effects and Interactions in Completely Randomized Factorial Designs When Time to Event is the Outcome.

Barry Kurt Moser1, Susan Halabi1.   

Abstract

In this paper we develop the methodology for designing clinical trials with any factorial arrangement when the primary outcome is time to event. We provide a matrix formulation for calculating the sample size and study duration necessary to test any effect with a pre-specified type I error rate and power. Assuming that a time to event follows an exponential distribution, we describe the relationships between the effect size, the power, and the sample size. We present examples for illustration purposes. We provide a simulation study to verify the numerical calculations of the expected number of events and the duration of the trial. The change in the power produced by a reduced number of observations or by accruing no patients to certain factorial combinations is also described.

Entities:  

Year:  2015        PMID: 25530661      PMCID: PMC4270194          DOI: 10.1080/03610926.2012.705940

Source DB:  PubMed          Journal:  Commun Stat Theory Methods        ISSN: 0361-0926            Impact factor:   0.893


  18 in total

1.  Detecting treatment-by-centre interaction in multi-centre clinical trials.

Authors:  R F Potthoff; B L Peterson; S L George
Journal:  Stat Med       Date:  2001-01-30       Impact factor: 2.373

2.  Sample size determination for comparing several survival curves with unequal allocations.

Authors:  Susan Halabi; Bahadur Singh
Journal:  Stat Med       Date:  2004-06-15       Impact factor: 2.373

Review 3.  Some controversies in planning and analysing multi-centre trials.

Authors:  S Senn
Journal:  Stat Med       Date:  1998 Aug 15-30       Impact factor: 2.373

4.  Planning the size and duration of a clinical trial studying the time to some critical event.

Authors:  S L George; M M Desu
Journal:  J Chronic Dis       Date:  1974-02

5.  Power considerations for testing an interaction in a 2 x k factorial design with a failure time outcome.

Authors:  A H Xiang; H N Sather; S P Azen
Journal:  Control Clin Trials       Date:  1994-12

6.  The 2 x 2 factorial design: its application to a randomized trial of aspirin and carotene in U.S. physicians.

Authors:  M J Stampfer; J E Buring; W Willett; B Rosner; K Eberlein; C H Hennekens
Journal:  Stat Med       Date:  1985 Apr-Jun       Impact factor: 2.373

7.  Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation.

Authors:  L V Rubinstein; M H Gail; T J Santner
Journal:  J Chronic Dis       Date:  1981

8.  Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.

Authors:  Joseph O Moore; Stephen L George; Richard K Dodge; Philip C Amrein; Bayard L Powell; Jonathan E Kolitz; Maria R Baer; Frederick R Davey; Clara D Bloomfield; Richard A Larson; Charles A Schiffer
Journal:  Blood       Date:  2004-11-30       Impact factor: 22.113

Review 9.  Analysis and reporting of factorial trials: a systematic review.

Authors:  Finlay A McAlister; Sharon E Straus; David L Sackett; Douglas G Altman
Journal:  JAMA       Date:  2003-05-21       Impact factor: 56.272

10.  A computer program for sample size and power calculations in the design of multi-arm and factorial clinical trials with survival time endpoints.

Authors:  R Natarajan; B W Turnbull; E H Slate; L C Clark
Journal:  Comput Methods Programs Biomed       Date:  1996-03       Impact factor: 5.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.